Do you ever consider intermittent ADT for metastatic prostate cancer?
The Intergroup 0162 trial did not demonstrate noninferiority, although OS difference only 5.1 vs. 5.8 yrs. Would pattern of spread affect your decision (i.e. oligometastatic recurrence after primary therapy with plan for local therapy to the met)?
Community PollStarted
Do you ever recommend intermittent ADT for metastatic prostate cancer?
111 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Michigan Medical School
Answered on
In general, I recommend continuous ADT for men with metastatic disease based on the OS difference from the Intergroup 0162 trial. I do agree, however, that this trial was a noninferiority design and the difference is not large, therefore in men with very limited disease who display intolerance to AD...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on
Most men with mHSPC deserve a trial of continuous ADT plus further intensification of therapy with a potent AR inhibitor (abi, enza, darolutamide, apalutamide) or docetaxel, and treatment of the primary, all of which provide level 1 survival benefits in certain contexts depending on volume of diseas...
Join for free or sign in to see the full answer